Icagen Inc. has disclosed potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of pain, Alzheimer’s disease, epilepsy, motor neuron disease, neurodevelopmental disorders, depression, tinnitus and attention deficit hyperactivity disorder, among others.